They changed the name. The part worth noticing is why. In May, polycystic ovary syndrome stopped being called polycystic ovary syndrome. After fourteen years of work involving 56 patient and professional organisations and more than 22,000 survey responses, a consensus published in The Lancet renamed it polyendocrine metabolic ovarian syndrome — PMOS.[1]
The old term, the authors wrote, was inaccurate: it implied pathological ovarian cysts, obscured the endocrine and metabolic features, and contributed to delayed diagnosis and stigma. A companion paper found no increase in abnormal ovarian cysts in the condition at all.[1]
Renaming a syndrome sounds like paperwork. It isn’t.
For two decades, the name pointed a torch at the ovaries — which is why so many women were told to come back when they wanted to get pregnant, and not before. The cysts were never the disease. They were a downstream signal.
What was actually going on underneath
“Polyendocrine” acknowledges multiple interacting hormonal disturbances — insulin, androgens, neuroendocrine hormones — rather than an isolated ovarian problem. “Metabolic” names the insulin resistance, and the raised long‑term risk of type 2 diabetes and cardiovascular disease.[2]
The insulin numbers are the ones to sit with. Insulin resistance is present in up to 75% of women with the condition even at normal BMI, and in nearly 95% of those with overweight or obesity. Insulin resistance drives excess androgen production, which disrupts follicle development, which stops ovulation. The irregular cycle is the last domino, not the first.[2]
Which is also why the risks never stopped at fertility. Higher lifetime rates of type 2 diabetes, gestational diabetes, dyslipidaemia, hypertension, fatty liver disease and sleep apnoea — persisting well past the reproductive years.[3]
The Indian numbers are their own argument
We finally have proper national data, and it’s recent. The ICMR task force study screened 9,824 women aged 18 to 40 across the country. Weighted national prevalence came in at 7.2% by the stricter NIH criteria and 19.6% by Rotterdam criteria. Roughly one in five, by the diagnostic standard most Indian clinicians actually use.[4]
The comorbidity picture is the part that should have made front pages. Among Indian women with the condition: 91.9% had dyslipidaemia, 32.9% had non‑alcoholic fatty liver disease, 24.9% had metabolic syndrome, 43.2% had obesity, 8.3% had hypertension. Nine in ten with disordered lipids. A third with fatty liver — in women mostly in their twenties and thirties.[4]
And then the thing that makes this specifically ours. South Asian bodies carry more intra‑abdominal and truncal fat than white European bodies at the same weight, plus more fat deposited in the liver and skeletal muscle — which produces greater insulin resistance at a lower BMI. It’s why Asian Indian cut‑offs are set lower: 23 kg/m² for overweight, 25 for obesity, and a waist of 80 cm for abdominal obesity in women.[5]
So the woman who gets told her BMI is fine may be sitting at the exact BMI where her risk starts. Kerry’s nutrition science team makes the same point about the rename: women in South Asia and Asia‑Pacific show higher insulin resistance at lower BMI, which is precisely why the metabolic framing matters more here than almost anywhere.[5]
The woman who gets told her BMI is fine may be sitting at the exact BMI where her risk starts.
Worth noting that Indian clinicians aren’t uniformly delighted with the new name either. A letter in The Lancet — from an endocrinologist in Bengaluru, among others — argues that “polyendocrine” usually implies failure of multiple endocrine glands, which isn’t quite what’s happening here. Fair objection. The transition is being rolled out over three years anyway, so there’s time.[1]
What actually moves the needle
The 2023 international guideline puts lifestyle first — not because it’s the gentle option, but because it targets the mechanism.[6]
On the plate
No single diet has won. What consistently works is lowering the glycaemic load, which in an Indian kitchen is less about elimination than about restructuring. White rice, maida‑based rotis, poha, upma, idli and dosa made from over‑fermented refined batter — none of these are villains, but a meal that is 70% refined starch and 10% protein is a blood‑sugar event.[6]
The fixes are unglamorous: eat the dal and the curd and the vegetable before the rice, cut the rice portion by a third and replace the volume with protein, and stop treating fruit juice and “healthy” granola as neutral.
Protein is the gap most urban Indian women have. Most of us are running well under what’s needed to hold muscle, and muscle is where glucose goes. Curd, paneer, eggs, chicken, fish, dals paired with grains, whey if it’s easier — spread across the day rather than dumped into dinner.[6]
The other lever nobody mentions: sleep and meal timing. Eating dinner at 10:30 pm because that’s when the day ends is a metabolic decision, not a scheduling one.
On the move
This is where the guidance is unusually specific, and where most of us are underdosing.
The baseline is 150 minutes a week of moderate activity or 75 minutes of vigorous. For weight change and prevention of regain, the target rises to 250 minutes moderate or 150 minutes vigorous, plus muscle‑strengthening on two non‑consecutive days. And because insulin action is the point, the position statement recommends exercising daily, or at minimum every second day.[7]
That last line reframes everything. Insulin sensitivity improves after a session and fades within roughly 48 hours. Three long weekend workouts and five sedentary days is not the same stimulus as thirty minutes most days, even if the weekly total matches.[7]
Meta‑analysis found that vigorous aerobic exercise and resistance training both produced moderate reductions in HOMA‑IR versus control. Strength training deserves more attention than it gets here specifically — the South Asian pattern includes lower skeletal muscle mass per kilogram of body weight, and muscle is where the glucose‑absorbing machinery lives. Two or three sessions a week of actual load. Not pink dumbbells.[8]
On supplements
Inositol is the one every algorithm will serve you. Be a little careful with the certainty. The systematic review that informed the 2023 guideline concluded that evidence suggests benefits for some metabolic measures, but that the overall evidence base is limited and inconclusive — and recommended shared decision‑making rather than blanket use.[9]
Where it is used, myo‑inositol alone shows positive results, and the myo‑to‑D‑chiro combination appears effective at ratios of at least 40:1. Typical dosing studied is 4 g of myo‑inositol daily, with comparable cycle‑regularity effects to metformin in some trials.[9]
Vitamin D is worth correcting if you’re deficient, which — in this country, with this much indoor life — you probably are. Test rather than guess.[10]
The one thing to take away
If you were told at twenty‑four that you had PCOS, handed a strip of pills, and told to come back when you wanted a baby — you were given a reproductive diagnosis for a metabolic condition. That was the state of the science then. It isn’t now.[1, 2]
The questions worth asking at your next appointment aren’t about your ovaries. They’re fasting insulin, HbA1c, a full lipid panel, a liver ultrasound if there’s any flag, and a waist measurement against the 80 cm line rather than the BMI chart on the wall. The new name exists to make that conversation the default one.[2, 5]
The rest is catching up to what we should have been measuring all along.
0 comments